Literature DB >> 33804181

Genetic Drivers of Head and Neck Squamous Cell Carcinoma: Aberrant Splicing Events, Mutational Burden, HPV Infection and Future Targets.

Zodwa Dlamini1, Mohammed Alaouna2, Sikhumbuzo Mbatha3, Ahmed Bhayat4, Mzubanzi Mabongo5, Aristotelis Chatziioannou1,6,7, Rodney Hull1.   

Abstract

Head and neck cancers include cancers that originate from a variety of locations. These include the mouth, nasal cavity, throat, sinuses, and salivary glands. These cancers are the sixth most diagnosed cancers worldwide. Due to the tissues they arise from, they are collectively named head and neck squamous cell carcinomas (HNSCC). The most important risk factors for head and neck cancers are infection with human papillomavirus (HPV), tobacco use and alcohol consumption. The genetic basis behind the development and progression of HNSCC includes aberrant non-coding RNA levels. However, one of the most important differences between healthy tissue and HNSCC tissue is changes in the alternative splicing of genes that play a vital role in processes that can be described as the hallmarks of cancer. These changes in the expression profile of alternately spliced mRNA give rise to various protein isoforms. These protein isoforms, alternate methylation of proteins, and changes in the transcription of non-coding RNAs (ncRNA) can be used as diagnostic or prognostic markers and as targets for the development of new therapeutic agents. This review aims to describe changes in alternative splicing and ncRNA patterns that contribute to the development and progression of HNSCC. It will also review the use of the changes in gene expression as biomarkers or as the basis for the development of new therapies.

Entities:  

Keywords:  aberrant splicing events; head and neck squamous cell carcinoma (HNSCC); human papillomavirus (HPV) infection; methylation; mutational burden; non-coding RNA (ncRNA)

Mesh:

Substances:

Year:  2021        PMID: 33804181      PMCID: PMC7998272          DOI: 10.3390/genes12030422

Source DB:  PubMed          Journal:  Genes (Basel)        ISSN: 2073-4425            Impact factor:   4.096


  136 in total

1.  Lysyl oxidase-like 2 is highly expressed in colorectal cancer cells and promotes the development of colorectal cancer.

Authors:  Ximao Cui; Guanghui Wang; Wenbin Shen; Zhenyu Huang; Hailan He; Long Cui
Journal:  Oncol Rep       Date:  2018-05-21       Impact factor: 3.906

2.  Cyclin A1 is a transcriptional target of PITX2 and overexpressed in papillary thyroid carcinoma.

Authors:  Yan Liu; Yue Huang; Guo-Zhang Zhu
Journal:  Mol Cell Biochem       Date:  2013-09-04       Impact factor: 3.396

3.  p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer.

Authors:  N Murphy; M Ring; C C B B Heffron; B King; A G Killalea; C Hughes; C M Martin; E McGuinness; O Sheils; J J O'Leary
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

4.  Differential regulation of gene expression by PITX2 isoforms.

Authors:  Carol J Cox; Herbert M Espinoza; Bryan McWilliams; Kimberly Chappell; Lisa Morton; Tord A Hjalt; Elena V Semina; Brad A Amendt
Journal:  J Biol Chem       Date:  2002-04-10       Impact factor: 5.157

5.  Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers.

Authors:  Curtis R Pickering; Jiexin Zhang; Suk Young Yoo; Linnea Bengtsson; Shhyam Moorthy; David M Neskey; Mei Zhao; Marcus V Ortega Alves; Kyle Chang; Jennifer Drummond; Elsa Cortez; Tong-Xin Xie; Di Zhang; Woonbok Chung; Jean-Pierre J Issa; Patrick A Zweidler-McKay; Xifeng Wu; Adel K El-Naggar; John N Weinstein; Jing Wang; Donna M Muzny; Richard A Gibbs; David A Wheeler; Jeffrey N Myers; Mitchell J Frederick
Journal:  Cancer Discov       Date:  2013-04-25       Impact factor: 39.397

6.  AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.

Authors:  David Hong; Razelle Kurzrock; Youngsoo Kim; Richard Woessner; Anas Younes; John Nemunaitis; Nathan Fowler; Tianyuan Zhou; Joanna Schmidt; Minji Jo; Samantha J Lee; Mason Yamashita; Steven G Hughes; Luis Fayad; Sarina Piha-Paul; Murali V P Nadella; Morvarid Mohseni; Deborah Lawson; Corinne Reimer; David C Blakey; Xiaokun Xiao; Jeff Hsu; Alexey Revenko; Brett P Monia; A Robert MacLeod
Journal:  Sci Transl Med       Date:  2015-11-18       Impact factor: 17.956

7.  SUMO conjugation to spliceosomal proteins is required for efficient pre-mRNA splicing.

Authors:  Berta Pozzi; Laureano Bragado; Cindy L Will; Pablo Mammi; Guillermo Risso; Henning Urlaub; Reinhard Lührmann; Anabella Srebrow
Journal:  Nucleic Acids Res       Date:  2017-06-20       Impact factor: 16.971

8.  Regulation of epidermal growth factor receptor signaling and erlotinib sensitivity in head and neck cancer cells by miR-7.

Authors:  Felicity C Kalinowski; Keith M Giles; Patrick A Candy; Alishum Ali; Clarissa Ganda; Michael R Epis; Rebecca J Webster; Peter J Leedman
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

9.  Micro-ribonucleic acid expression profiling and bioinformatic target gene analyses in laryngeal carcinoma.

Authors:  Zhong-Ming Lu; Ye-Feng Lin; Li Jiang; Liang-Si Chen; Xiao-Ning Luo; Xin-Han Song; Shao-Hua Chen; Si-Yi Zhang
Journal:  Onco Targets Ther       Date:  2014-04-05       Impact factor: 4.147

10.  Tumour-suppressive microRNA-29s inhibit cancer cell migration and invasion by targeting laminin-integrin signalling in head and neck squamous cell carcinoma.

Authors:  T Kinoshita; N Nohata; T Hanazawa; N Kikkawa; N Yamamoto; H Yoshino; T Itesako; H Enokida; M Nakagawa; Y Okamoto; N Seki
Journal:  Br J Cancer       Date:  2013-10-03       Impact factor: 7.640

View more
  2 in total

Review 1.  Role of Salivary MicroRNA and Cytokines in the Diagnosis and Prognosis of Oral Squamous Cell Carcinoma.

Authors:  Francisco Javier Manzano-Moreno; Victor J Costela-Ruiz; Enrique García-Recio; Maria Victoria Olmedo-Gaya; Concepción Ruiz; Candelaria Reyes-Botella
Journal:  Int J Mol Sci       Date:  2021-11-11       Impact factor: 5.923

Review 2.  Alternative RNA Splicing-The Trojan Horse of Cancer Cells in Chemotherapy.

Authors:  Nikolay Mehterov; Maria Kazakova; Yordan Sbirkov; Boyan Vladimirov; Nikolay Belev; Galina Yaneva; Krassimira Todorova; Soren Hayrabedyan; Victoria Sarafian
Journal:  Genes (Basel)       Date:  2021-07-18       Impact factor: 4.096

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.